RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours

A Phase I/II Study of RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours

The study will evaluate safety and immunological response to RhoC peptide vaccine in patients with prostate cancer

Inclusion Criteria:

• Patients prostatectomised (PT) due to histologically verified adenocarcinoma of the prostate gland who currently are not being treated, or expected within the next 8 months to be treated, with any anti-cancer treatment.
• ECOG performance status 0 or 1.

Exclusion Criteria:

• Patient has been treated with Androgen Deprivation Therapy (ADT), or expected to receive such treatment within the next 8 months from enrolment.
• Severe medical conditions, such as but not limited to severe asthma/chronic obstructive pulmonary disease (COPD), New York Heart Association (NYHA) grading 3 or above, poorly regulated insulin dependent diabetes, any significant organ damage as judged by the Investigator.